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■ LETTER TO THE EDITOR ■
Ovarian hyperstimulation syndrome (OHSS) is a poten-
tially severe complication following ovarian stimulation.
It has a clinical spectrum ranging from a mild form,
which accounts for most cases, to moderate and severe
forms that occur rarely but deserve special attention
since they are life threatening [1]. Clinical manifestations
of OHSS can be classified into (1) mild, with abdominal
distension; (2) moderate, with ascites; (3) severe, with
apparent ascites and/or effusion (pleural, rarely peri-
cardial); and (4) hypovolemic shock, acute renal and
respiratory failure, and thrombotic disorders [2]. This
syndrome is an iatrogenic disorder, which is not yet fully
understood, and carries a significant risk of morbidity
and mortality. Despite close monitoring during ovarian
stimulation and rigid guidelines and criteria for cancel-
ing cycles, OHSS still occurs. Owing to the increased
use of therapeutic strategies for infertility, the pulmo-
nary complication of this syndrome should be suspected
on clinical grounds and identified early to allow for
more appropriate diagnosis and management [3]. We
report a patient whose only manifestation of OHSS
was unilateral pleural effusion with no ascites.
A 35-year-old woman came to our hospital for in vitro
fertilization and embryo transfer treatment because of
bilateral tubal occlusion. She received oral pills and stan-
dard downregulation during the previous cycle before
ovarian stimulation. Ovulation induction, using recom-
binant follicle stimulating hormone (r-FSH; 225 IU/
day for 8 days, up to a dose of 1650 IU) and human
menopausal hormone (HMG; 150 IU/day for 3 days,
up to a dose of 450 IU), was then started on day 3 after
the cycle began. Human chorionic gonadotropin (hCG)
10,000 IU was administrated when at least two follicles
were ≥ 16 mm. The level of estradiol (E2) on the day
of hCG administration was 2,052 pg/mL. There were
eight oocytes harvested in this cycle, and three embryos
were transferred back to her uterus after oocyte re-
trieval. Luteal phase support was given with oral prog-
esterone without hCG. The postoperative course was
uneventful until the day she came to the emergency
room (ER).
Approximately 2 weeks following embryo transfer,
she presented in our ER with severe dyspnea. On admis-
sion, the chest X-ray revealed a large isolated pleural
effusion in the right lung (Figure 1). There was no ascites
or extraordinary enlarged ovaries within her abdomen.
There was no sign of hemoconcentration either. Her
white blood cell (WBC) count, hemoglobin level, and
hematocrit (Hct) were 15,900/µL, 13.6 g/dL, and 38.6%,
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Accepted: December 18, 2006 Figure 1. Severe pleural effusion in the right lung field.
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respectively. The electrolytes, and renal and hepatic para-
meters were all within normal limits. Her urine output
was also normal. Conservative treatment with albumin
infusion (albumin, 50 mg/day for 6 days, up to a dose
of 300 mg) followed by diuretics was given during the
6-day admission period, and the pleural effusion dis-
appeared gradually and completely (Figures 2 and 3).
The patient had an uneventful pregnancy and delivery.
OHSS is defined as an iatrogenic complication of
ovarian stimulation. It can be extremely severe, with mor-
bidity reaching 5% of in vitro fertilizations [4]. A recent
Canadian study of 771 patients treated with gonad-
otropins reported that severe OHSS occurred in 22
patients (3%), pleural effusion occurred in 5 (1%), and
only one required thoracentesis (0.1%) [5]. OHSS is
characterized by ovarian enlargement and increased vas-
cular permeability, leading to marked transudation of
a protein rich fluid from the vascular compartment into
the peritoneal, pleural or, to a lesser extent, pericardial
cavities. The intensity of the syndrome is related to the
degree of ovarian follicular response to the ovulation-
inducing agents. The syndrome can fall into four clinical
categories of increasing severity: (1) mild, with abdomi-
nal distension and discomfort; (2) moderate, with ascites
on ultrasound examination; (3) severe, with a clinically
apparent ascites, with or without another effusion (pleu-
ral, rarely pericardial), and a hemoconcentration (Hct,
45%; WBC, 15,000/µL); and (4) critical, with, in addition
to the above signs, hypovolemic shock, acute renal and
respiratory failure, a marked hemoconcentration (Hct,
55%; WBC, 25,000/µL), and thrombotic disorders [2].
It has been shown that the development of OHSS
is associated with the release of vasoactive substances
into the peritoneal cavity and systemic circulation, either
directly from the ovary or via an intermediate substance
released from the ovary, causing increased capillary
permeability and a shift of fluid from the intravascular
volume into the third space [6]. The pathogenesis of
OHSS is generally believed to represent the overpro-
duction or altered expression of vasoactive substances
of ovarian origin that are critical for follicle release or
neovascularization of the developing corpus luteum [1].
Recent evidence argues for a critical role of several medi-
ators, including various cytokines such as interleukin
IL-1, IL-6, IL-8, and tumor necrosis factor. More recently,
vascular endothelial growth factor has been identified
as playing a significant role in the pathogenesis of
OHSS in humans [2,6].
The unpredictable individual responses to ovulation
inducers make the prevention of OHSS very difficult.
Appropriate information should be given to the patient
regarding the potential risks of the procedure [4]. The
following risk factors have been identified: age younger
than 35 years, the presence of a polycystic ovarian 
disease prior to stimulation, number of follicles > 10,
estradiol serum concentration > 2,000 pg/mL, and an
ongoing active pregnancy [1,7].
The case we report herein was atypical because of
the isolated nature of the pleural effusion in the absence
of ascites and hemoconcentration. Isolated hydrotho-
rax may result from the combination of positive intra-
abdominal pressure, negative intrathoracic pressure
Figure 2. Moderate pleural effusion in the right lung field. Figure 3. Complete resolution of the pleural effusion.
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and diaphragmatic defects that promote the transfer
of intra-abdominal fluid into the pleural fluid, result-
ing in hydrothorax in the absence of abdominal fluid
[8,9]. In our case and other reported cases, this prefer-
ential location might be explained by a capillary leak and
exudation into the plural space due to decreased right
lymphatic drainage compared to the left side [10,11].
In addition, the explanation involving defects in the
tendinous portion of the diaphragm, more common in
women and on the right side, which allows for, under
the suctioning effect of negative intrathoracic pres-
sure, accumulation of ascitic fluid in the thorax, seems
to be a logical proposition [12–14].
In conclusion, OHSS presenting with isolated pleu-
ral effusion usually has a benign course and sponta-
neously favorable outcome. Unilateral pleural effusion
is usually in the right lung because of a decreased right
lymphatic drainage as compared to the left side, in
addition to the possible explanation of diaphragmatic
defect. The physician should be aware of this syn-
drome and the possibility of unilateral hydrothorax as
the sole symptom of OHSS, in order to ensure better
and minimal management of these potentially pregnant
patients. Albumin infusion might be a safe and effici-
ent option for the treatment of unilateral hydrothorax
without thoracentesis.
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